Novel Treatments in Improving Renal Outcomes in Light Chain Cast Nephropathy
Part of paid clinical trials in Boston, Massachusetts.
- Sponsor
- Brigham and Women's Hospital
- Study ID
- NCT06483139
- Status
- Recruiting
Conditions
- Acute Kidney Injury
- Light Chain Nephropathy
- Multiple Myeloma
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Accepted
Interventions
- Plasma exchange — PROCEDUREPatients treated with plasma exchange within 30 days of diagnosis of light chain cast nephropathy Patients not treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
- Daratumumab — DRUGPatients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
Study Details
Objective 1: To test whether treatment with plasma exchange improves renal recovery in patients with light chain cast nephropathy Objective 2: To compare renal outcomes among patients treated with plasma exchange versus daratumumab-based regimens versus non-daratumumab based-regimens.
Key Dates
- Start date
- Jun 1, 2024
- Status verified
- Nov 2025
- Primary completion
- Jun 1, 2026
- Completion
- Jun 1, 2026
Study Design
- Enrollment
- 450 participants (estimated)
Arms
- Arm: Patients treated with plasma exchangeTreated with plasma exchange ithin 30 days of diagnosis of light chain cast nephropathy
- Arm: Patients not treated with plasma exchangePatients not treated with plasma exchange within 30 days of diagnosis of light chain cast nephropathy
- Arm: Patients treated with daratumumabPatients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
- Arm: Patients not treated with daratumumabPatients treated with daratumumab within 30 days of diagnosis of light chain cast nephropathy
Primary Outcome Measure
The primary composite outcome is the rate of survival with renal recovery within 90 days from the diagnosis of light chain cast nephropathy. [ Time Frame: 90 days ]
Central Contacts
- Shruti Gupta, MD5712366626
- Christina Shincovich, MD
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Brigham and Women's Hospital | Boston | Massachusetts | 02130 | Shruti Gupta |
Find similar trials in Boston, MA
By condition
By specialty
By research site
Related Studies
- Collection of Samples and Clinical Data From Patients With Amyloid DiseasesRecruiting · Boston Medical Center · Boston, Massachusetts
- Integrated Cancer Repository for Cancer ResearchRecruiting · University of Nebraska · Greenwood Village, Colorado
- Predicting Progression of Developing Myeloma in a High-Risk Screened Population (PROMISE)Recruiting · Dana-Farber Cancer Institute · Boston, Massachusetts
- Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.PHASE1 · Recruiting · Newave Pharmaceutical Inc · Chicago, Illinois